fda warning letters glp-1 compounders september 2025 news issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Congress Introduces SAFE Drugs Act

R., Bryant, M

Nevertheless, patients using insulin or sulfonylureas may require dose adjustments when initiating potent incretin-based therapy because improved glycemia and reduced caloric intake can increase hypoglycemia risk when combined with therapies that independently lower glucose

Interventions included liraglutide, semaglutide, tirzepatide, and other GLP-1RAs

Depo-Provera, a contraceptive injection, has been linked to an increased risk of developing brain tumors (including glioblastoma and meningioma)

The class of medications called GLP-1 agonists has received a ton of media attention and rumor-mongering

Your provider should assess your individual risk-benefit profile before deciding